2 分鐘認識 CRISPR/Cas9 基因編輯技術 (CRISPR/Cas 9 Gene Editing Introduction)
Posted by btwatson on January 25, 2018 2:08 pm
Tags:
Categories:
Crispr
2 分鐘認識 CRISPR/Cas9 基因編輯技術 (CRISPR/Cas 9 Gene Editing Introduction)
近幾年最熱門的基因編輯技術 CRISPR/Cas9 介紹,這個從原核生物發現的免疫系統,因為其專一性與簡易性,現已可以用於各種生物技術的 DNA 基因編輯實驗 (in vitro 或者 in vivo),不到 2 分鐘的小動畫就能對 CRISPR 有簡單認識,一起來看看吧~
Crispr News
-
Could CRISPR gene editing raise cancer risks? - Genetic Literacy ProjectAugust 9, 2022
-
Plant Breeding and CRISPR Plants Market 2022 Upcomming Big Trends | Bayer, Syngenta, KWS, DowDuPont – Shanghaiist - ShanghaiistAugust 9, 2022
-
Crispr: My Long Term 'Wait And Watch' Punt On The Future Of Gene Editing (NASDAQ:CRSP) - Seeking AlphaAugust 8, 2022
-
New portable diagnostic detects SARS-CoV-2 RNA and antibodies at the same time - EurekAlertAugust 8, 2022
-
CRISPR Therapeutics GAAP EPS of -$2.40 misses by $0.19, revenue of $0.16M misses by $2.04M (NASDAQ:CRSP) - Seeking AlphaAugust 8, 2022
-
CRISPR THERAPEUTICS AG Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.comAugust 8, 2022
-
Pfizer bets $5.4bn against gene therapies in sickle cell - Evaluate PharmaAugust 8, 2022
-
Epigenic Therapeutics raises $20M for gene editing technology - Labiotech.euAugust 8, 2022
-
Episode 11 - CRISPR with Dr Jakob Haaber & Dr Richard Fox - Drug Target ReviewAugust 8, 2022
-
CRISPR and Cas Genes Market Size, Scope, Growth Opportunities, Trends by Manufacturers And Forecast to 2029 – Shanghaiist - ShanghaiistAugust 8, 2022
-
Vertex: Q2 2022 Earnings Steady - But Expect Volatility Soon (NASDAQ:VRTX) - Seeking AlphaAugust 5, 2022
-
New Products Posted to GenomeWeb: Thermo Fisher, Seer, Novacyt, Artisan Bio, More - GenomeWebAugust 5, 2022
-
'TnpB protein, a new tool in CRISPR-Cas gene editing' - KBRAugust 5, 2022
-
Cancers and heart disease could be diagnosed more easily with new rapid test - Imperial College LondonAugust 4, 2022
-
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Yahoo FinanceAugust 4, 2022
- CRISPR rivals put patents aside to help in fight against Covid-19 – STAT
- CRISPR 2.0: Base Editing in the Groove – Genetic Engineering & Biotechnology News
- The Promises of CRISPR Genome Editing in Biomedicine – Labiotech.eu
- The Code Breaker and Crispr People — the ethics of editing humanity – Financial Times
- ERS Genomics Licenses CRISPR Patents to CRO ZeClinics – GenomeWeb
- The Dark Side of CRISPR – Scientific American
- ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement – BioSpace
- Scientists Use CRISPR To Create Model of AML Progression – AJMC.com Managed Markets Network
- DECODR app identifies DNA mutations from CRISPR gene therapies – European Pharmaceutical Review
- CRISPR/Cas technology as a promising weapon to combat viral infections – Wiley
- Neanderthal-like ‘mini-brains’ created in lab with CRISPR – Nature.com
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – Phys.org
- Affordable CRISPR app reveals unintended mutations at site of CRISPR gene repair – EurekAlert
- New CRISPR tech targets human genome’s complex code: Programmable CRISPR/Cas9-based kinase offers insights into, control over regulatory histone proteins – Science Daily
- After ditching Editas, AbbVie taps Caribou for new CRISPR, CAR-T pact – FierceBiotech
Leave a Reply
You must be logged in to post a comment.